Targets › TNFRSF13B
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2029.
Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. (UniProt, O14836)
Open in Phaseline: the race on TNFRSF13B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Aurinia Pharmaceuticals | Aritinercept BAFF receptor (BAFF-R) agonist | TNFRSF13B | Phase 1 | Myasthenia Gravis, Generalized | Mar 2029 |
Myasthenia Gravis, Generalized (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.